Skip to content
Muscular Dystrophy News logo
  • About MD
    What is muscular dystrophy?
    Causes
    Types
    Symptoms
    Diagnosis
    Living with muscular dystrophy
    Treatments
    • Approved treatments
    • Experimental treatments
    • Non-drug treatments
  • News
  • Columns
    Duchenne: Shalom’s Lifelong Partner-in-Crime — Shalom Lim Ern Rong
    Muscle Memoirs: LGMD Experiences — Patrick Moeschen
    Party of 9 — Betty Vertin
    Working Through the Process — Robin Stemple
    Archived columns
    • Bloom – Prudence Jones
    • Hawk’s-Eye View – Hawken Miller
    • Hidden Truths – Adeel Rizvi
    • Of Dragons and Dystrophin – Andy Rusch
  • Featured topics
    Caregiver’s guide
    • Videos: By your side
    • DMD pain management
    • Navigating school with DMD
    • Caring for someone with DMD
    • Navigating DMD as a family
    • Raising a child with DMD
    • Daily life with DMD
    • Resources and support
    • Exon-skipping therapies
    • Gene therapy
    • View all
    Adaptive living
    • Ambulatory care plan
    • DMD care plan
    • DMD myths and facts
    • Managing osteoporosis
    • Personal stories
    • Assistive technology
    • Home adaptations
    • Love and relationships with DMD
    • DMD life skills
    Empowering every stage
    • Videos: Partners in progress
    • DMD caregiving
    • DMD diagnosis
    • Managing the day-to-day
    • DMD and genetics
    • DMD and the heart
    • Caregiving highs and lows
    • DMD medical team
  • Forums
  • Advocacy partners
  • What can we help you find today?

October 18, 2017 News by Iqra Mumal, MSc

Researchers Encouraged by Early Effectiveness, Safety Profile of Tricyclo-DNA in DMD Animal Study

Tricyclo-DNA (tcDNA), a class of therapeutics known as antisense oligonucleotides (AONs), has shown an important degree of effectiveness and a promising safety profile in a preclinical study with mice. The goal of the study is to test tcDNA’s potential use in treating Duchenne Muscular Dystrophy (DMD). The study, “Efficacy and…

February 6, 2015 News by Patricia Inácio, PhD

tcDNA-antisense Oligonucleotides Offer Promising, New Therapeutics for Duchenne Muscular Dystrophy

A new study entitled “Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers” shows a new class of antisense oligonucleotides – tcDNA- antisense oligonucleotides – are highly efficient at rescuing dystrophin levels and improving symptoms in a mouse model of Duchenne muscular dystrophy.

Recent Posts

  • DMD gene therapy Elevidys wins conditional approval in Japan
  • When things go wrong, try to maintain an attitude of gratitude
  • Nonprofit releases updated PJ Nicholoff Steroid Protocol for DMD
  • Solve FSH invests $3M to advance ARM-201 as FSHD treatment
  • MDAS gala reminds me why I advocate for my community
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.